The randomized, phase 3 BEACON CRC trial was a 3-arm study conducted in patients with pretreated metastatic CRC characterized by a BRAF V600E mutation.
This single-arm, phase 2 study of pembrolizumab in advanced solid tumor cancers did not limit patient enrollment based on tumor PD-L1 expression level.
Synchronous metastatic disease is characterized by the presence of metastatic lesions, in addition to the primary tumor, at diagnosis.
Even though older adults were prescribed second-line therapies less frequently than younger adults, patients had similar overall survival outcomes across age subgroups.
In this study, a young adult was defined as an individual who was 40 years or younger.
Previous genomic profiling studies have identified potentially targetable alterations in IDH1 and FGFR2 in primary tumor specimens of some patients with IHCC.
Researchers hypothesized that because prior studies have demonstrated that common drugs can affect the microbiome, these medications could also impact IO efficacy in HCC.
Pegvorhyaluronidase alfa is an enzyme that breaks down hyaluronan, thought to be a contributor to the structure of the tumor microenvironment in some pancreatic cancers.
Promising results from an earlier-phase study of FOLFOX plus pegilodecakin in metastatic PDAC refractory to gemcitabine provided a rationale for this study.
In this study, deterioration in specific PROs required a drop of at least 10 points from baseline.
The median change in HCC tumor size between responders and nonresponders was statistically significant.
Fewer treatment-related grade 3 or higher adverse events were reported in the avelumab arm compared with the chemotherapy arm.
Although the use of value pathways in oncology appeared to extend time to treatment failure, it did not appear to influence overall survival.
In this interim analysis, PFS rates were compared in PD-L1–defined biomarker subsets of patients receiving maintenance durvalumab or capecitabine.
In this study, patients were randomly assigned to receive standard-dose RT or standard-dose RT plus an integrated RT boost to the primary tumor.
Cancer Therapy Advisor’s coverage of the Gastrointestinal Cancers Symposium will reflect the theme of personalized care across multiple types of gastrointestinal cancers.